Nuvectis Pharma, Inc. (NASDAQ:NVCT) stock is trading lower after the company reported data from the Phase 1b study evaluating ...

Nuvectis Pharma (NVCT) stock falls as company posts interim data from a Phase 1b trial for its ovarian cancer drug candidate.

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

There are several stocks that passed through the screen and Nuvectis Pharma, Inc. (NVCT) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price ...

Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 ...

The worst performers were Sow Good Inc (NASDAQ:SOWG) which was down 56.78% to 4.24 in late trade, Wellchange Holdings Co Ltd ...

In a recent move that signals confidence in Nuvectis Pharma, Inc. (NASDAQ:NVCT), CEO and Chairman Ron Bentsur has increased his stake in the company through the purchase of ...

Nuvectis Pharma, Inc. (NASDAQ:NVCT – Free Report) – Stock analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Nuvectis Pharma in a report released on Tuesday, November 5th.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology.

Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of ...

Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ...